Q4 2025 Vir Biotechnology Inc Earnings Call Transcript
Key Points
- Vir Biotechnology Inc (VIR) announced a strategic collaboration with Estelas to advance the development and commercialization of VR 5,500, a promising T-cell engager for prostate cancer.
- The phase 1 data for VR 5,500 shows a compelling safety and efficacy profile, with no observed dose-limiting toxicities and limited low-grade cytokine release syndrome events.
- The collaboration with Estelas includes substantial financial terms, with potential combined upfront and milestone payments totaling $1.7 billion.
- The partnership allows Vir Biotechnology Inc (VIR) to accelerate the clinical development of VR 5,500 and expand trials to reach more patients, leveraging Estelas' global capabilities.
- Vir Biotechnology Inc (VIR) reported a reduction in R&D and SG&A expenses for 2025, demonstrating financial discipline and improved performance.
- The collaboration with Estelas is subject to the expiration or termination of the applicable waiting period under the Hart Scott Rodino Antitrust Improvements Act.
- Despite promising early data, the long-term durability of VR 5,500's efficacy remains to be fully established.
- The company faces substantial risks and uncertainties that could impact clinical development programs and collaboration outcomes.
- There is a need for further data to confirm the potential of VR 5,500 in earlier lines of metastatic castration-resistant prostate cancer therapy.
- The financial impact of the collaboration includes shared global development costs, with Vir Biotechnology Inc (VIR) contributing 40%.
Good afternoon and welcome to Vir Biotechnologies conference call to discuss the company's VIR-5500 strategic collaboration with Estelas in Positive phase 1 data and 2025 financial results. As a reminder, this conference call is being recorded at this time. (Operator Instructions)
I will now turn the call over to Kiki Patel, Head of Investor Relations. You may begin, Kiki.
Thank you, operator, and welcome everyone. Earlier today, we issued 3 press releases, including a joint release with Estelas announcing a strategic collaboration with our PSMA directed T-cell engager VR 5,500, a second release reporting the phase 1 VR 5,500 data that will be presented at AstoGU, and a third release reporting our fourth quarter and year-end earnings.
Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under applicable securities laws. These forward-looking statements involve substantial risks and uncertainties that could
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
